Newer Vaccines against Mosquito-borne Diseases

Review Article

Abstract

Mosquitos are responsible for a number of protozoal and viral diseases. Malaria, dengue, Japanese encephalitis (JE) and chikungunya epidemics occur commonly all over the world, leading to marked mortality and morbidity in children. Zika, Yellow fever and West Nile fever are others requiring prevention. Environmental control and mosquito bite prevention are useful in decreasing the burden of disease but vaccination has been found to be most cost-effective and is the need of the hour. RTS,S/AS01 vaccine is the first malaria vaccine being licensed for use against P. falciparum malaria. Dengvaxia (CYD-TDV) against dengue was licensed first in Mexico in 2015. A Vero-cell derived, inactivated and alum-adjuvanted JE vaccine based on the SA14–14-2 strain was approved in 2009 in North America, Australia and various European countries. It can be used from 2 mo of age. In India, immunization is carried out in endemic regions at 1 y of age. Another inactivated Vero-cell culture derived Kolar strain, 821564XY, JE vaccine is being used in India. Candidate vaccines against dengue, chikungunya and West Nile fever are been discussed. A continued research and development of new vaccines are required for controlling these mosquito-borne diseases.

Keywords

Mosquito-borne diseases Vaccines Children 

References

  1. 1.
    Caraballo H, King K. Emergency department management of mosquito-borne illness: malaria, dengue, and West Nile virus. Emerg Med Pract. 2014;16:1–23. quiz 23–4.Google Scholar
  2. 2.
    World Health Organization Japanese encephalitis. Available at: http://www.who.int/mediacentre/factsheets/fs386/en/. Accessed on 26th Jan 2017.
  3. 3.
    Centers for Disease Control and Prevention (CDC) Japanese Encephalitis - Chapter 3 - 2016 Yellow Book Travelers’ Health. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/japanese-encephalitis. Accessed on 21st Jan 2016.
  4. 4.
    Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2013;62:898–900.Google Scholar
  5. 5.
    Fischer M, Lindsey N, Staples JE, Hills S; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:1–27.Google Scholar
  6. 6.
    Advisory Committee on Vaccines and Immunization Practices of Indian Academy of Pediatrics (ACVIP of IAP). Available at: http://acvip.org/professional/columns/je-vaccines. Accessed on 23rd Jan 2017.
  7. 7.
    Wang SY, Cheng XH, Li JX, Li XY, Zhu FC, Liu P. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: a systematic review and meta-analysis. Hum Vaccin Immunother. 2015;11:1418–25.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kwon HJ, Lee SY, Kim KH, et al. The immunogenicity and safety of the live-attenuated SA 14-14-2 Japanese encephalitis vaccine given with a two-dose primary schedule in children. J Korean Med Sci. 2015;30:612–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sanchayan K, Fernandopulle R, Amarasinghe A, Thiyahiny SN, Sri Ranganathan S. Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 mo in National Immunisation Programme of Sri Lanka. Ceylon Med J. 2016;61:99–105.Google Scholar
  10. 10.
    Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188:1213–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Health AGD of. 4.8 Japanese encephalitis. Australian Government Department of Health. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-8. Accessed on 22nd Feb 2017.
  12. 12.
    Sricharoenchai S, Lapphra K, Chuenkitmongkol S, et al. Immunogenicity of a live attenuated chimeric Japanese encephalitis vaccine as a booster dose after primary vaccination with live attenuated SA14-14-2 vaccine: a phase IV study in Thai children. Pediatr Infect Dis J. 2017;36:e45–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Nasveld PE, Marjason J, Bennett S, et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin. 2010;6:906–14.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    World Health Organization. Yellow fever. Available at: http://www.who.int/ith/vaccines/yf/en/. Accessed on 24th Jan 2017.
  15. 15.
    Yf-Vax (Yellow Fever Vaccine): Side effects, interactions, warning, dosage & uses. Available at: http://www.rxlist.com/yellow-fever-vaccine-drug.htm. Accessed on 22nd Feb 2017.
  16. 16.
    Centers for Disease Control and Prevention (CDC) Vaccine Information Statement. Yellow Fever. Available at: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/yf.html. Accessed on 28th Jan 2017.
  17. 17.
    World Health Organization Malaria. Available at: http://www.who.int/gho/malaria/en/. Accessed on 16th Jan 2017.
  18. 18.
    Nussenzweig R, Vanderberg J, Most H. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med. 1969;134:1176–82.PubMedGoogle Scholar
  19. 19.
    Hill AVS. Vaccines against malaria. Philos Trans R Soc B Biol Sci. 2011;366:2806–14.CrossRefGoogle Scholar
  20. 20.
    Joint Technical Expert Group & World Health Organization. Background Paper on the RTS,S/AS01 Malaria Vaccine, 2015. Available at: http://www.who.int/immunization/sage/ meetings/2015/october/1_Final_malaria_vaccine_background_paper_v2015_09_30.pdf. Accessed on 22nd Jan 2017.
  21. 21.
    World Health Organization. Questions and answers on RTS,S/ASO1 malaria vaccine. Available at: http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/. Accessed on 18th Jan 2017.
  22. 22.
    The RTS SCTP. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–95.CrossRefGoogle Scholar
  23. 23.
    Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the global burden of disease study 2013. Lancet Infect Dis. 2016;16:712–23.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis. 2007;45:S56–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Guy B, Lang J, Saville M, Jackson N. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67:387–404.CrossRefPubMedGoogle Scholar
  26. 26.
    World Health Organization. Dengue. Available at: http://www.who.int/immunization/sage/meetings/2016/april/2_Smith_Clinical_Trial_Results_SAGE.pdf. Accessed on 24th Feb 2017.
  27. 27.
    World Health Organization. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine. 2017;35:1200–1.CrossRefPubMedGoogle Scholar
  28. 28.
    Rodriguez Melo FI, Morales JJR, De Los Santos AHM, Rivas E, Vigne C, Noriega F. Immunogenicity and safety of a booster injection of DTap-IPV//Hib (Pentaxim®) administered concomitantly with tetravalent dengue vaccine in healthy toddlers aged 15 to 18 mo in Mexico: a randomized trial. Pediatr Infect Dis J. 2017. doi:10.1097/INF.0000000000001542.
  29. 29.
    Godói IP, Pires Lemos LL, de Araújo VE, Bonoto BC, Godman B, Guerra Júnior AA. CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. J Comp Eff Res. 2017;6:165–80.CrossRefPubMedGoogle Scholar
  30. 30.
    World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization. Background paper on dengue vaccines prepared by the SAGE working group on Dengue vaccines. Available at: http://www.who.int/immunization/sage/meetings/2016/april/presentations_background_docs/en/. Accessed on 3rd Mar 2017.
  31. 31.
    Brandler S, Tangy F. Vaccines in development against West Nile virus. Viruses. 2013;5:2384–409.Google Scholar
  32. 32.
    Petrovsky N, Larena M, Siddharthan V, et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol. 2013;87:10324–33.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pierce KK, Whitehead SS, Kirkpatrick BD, et al. A live attenuated chimeric West Nile virus vaccine, rWN/DEN4Δ30, is well tolerated and immunogenic in Flavivirus-naive older adult volunteers. J Infect Dis. 2017;215:52–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Poore EA, Slifka DK, Raué H-P, et al. Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine. Vaccine. 2017;35:283–92.CrossRefPubMedGoogle Scholar
  35. 35.
    Durbin AP. Vaccine development for Zika virus-timelines and strategies. Semin Reprod Med. 2016;34:299–304.CrossRefPubMedGoogle Scholar
  36. 36.
    Testing Begins On An Experimental Zika Vaccine With Inactivated Virus. Available at: http://www.npr.org/sections/health-shots/2016/11/07/501015866/testing-begins-on-an-experimental-zika-vaccine-with-inactivated-virus. Accessed on 23rd Jan 2017.
  37. 37.
    World Health Organization. Chikungunya. Available at: http://www.who.int/mediacentre/factsheets/fs327/en/. Accessed on 28th Jan 2017.
  38. 38.
    Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012;11:1087–101.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Erasmus JH, Auguste AJ, Kaelber JT, et al. A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med advance online publication. Available at: http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4253.html. Accessed on 23rd Jan 2017.
  40. 40.
    Ramsauer K, Schwameis M, Firbas C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015;15:519–27.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  1. 1.Department of PediatricsUniversity College of Medical Sciences & Guru Tegh Bahadur HospitalNew DelhiIndia

Personalised recommendations